Novavax (NVAX) Confirms EMA is Reviewing COVID-19 Vaccine Filing for Conditional Marketing Authorization

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. HUMA
10. NVDA

Go back to Novavax (NVAX) Confirms EMA is Reviewing COVID-19 Vaccine Filing for Conditional Marketing Authorization

Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization

November 17, 2021 9:26 AM EST

GAITHERSBURG, Md., Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax' COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid. EMA's statement may be found... More